Synthesis and cytotoxic activities of spin-labeled derivatives of Cinobufagin

Abstract

Two series of novel spin-labeled derivatives of Cinobufagin(compounds 5 and 8a―8f in series 1 with five-membered ring nitroxyl free radical and compounds 6 and 9a―9f in series 2 with six-membered ring nitroxyl free radical) were synthesized. The cytotoxic activities in vitro against two tumor cell lines(HepG2 and HeLa) were evaluated, and the results indicate that all compounds display potent cytotoxicity against HepG2 and HeLa cells, and most compounds show better activities on HeLa cells than on HepG2 cells except for compounds 8a and 9d. Generally, the compounds in series 2 have more potent cytotoxic activity against HepG2 than the compounds in series 1. Especially, compounds 6 and 9f in series 2 exhibit even more potent activities against the two tumor cell lines than Cinobufagin. Thus incorporation of different L-amino acids as the linker changed the cytotoxic profile of the spin-labeled Cinobufagin. In addition, the representative compound 9f significantly changed the cell cycle distribution and led to HeLa cell cycle arrested at G₂/M phase.

Keywords

Cinobufagin / Nitroxyl free radical / Spin-labeled / Cytotoxic activity

References

[1] World Health Organization. World Cancer Day―"Together It Is Possible", 2012.

[2] Tan Y. F., Sun X. H., Dong F. Y., Tian H. Y., Jiang R. W. Chin. J. Chem., 2015, 33: 1084.

[3] Chen Q., Lin J. H., Zhao D., Zhu X. Chem. Res. Chinese Universi-ties, 2016, 32(4): 792.

[4] Hong Z., Chan K., Yeung H. W. J. Pharm. Pharmacol., 1992, 44: 1023.

[5] Wang J., Jin W., Jin H., Zhou F. China Journal of Chinese Materia Medica, 1998, 23: 651.

[6] Yeh J. Y., Huang W. J., Kan S. F., Wang P. S. The Prostate, 2003, 54: 112.

[7] Wang L., Wu J., Li M., Yang X. W., Cui J. R. Chin. J. Oncol., 2006, 27: 717.

[8] Wang X. L., Zhao G. H., Zhang J., Shi Q. Y., Guo W. X., Tian X. L., Qiu J. Z., Yin L. Z., Deng X. M., Song Y. J. Asian Nat. Prod. Res., 2011, 13: 383.

[9] Ye M., Ning L. L., Zhan J. X., Guo H. Z., Guo D. A. Journal of Mo-lecular Catalysis B, Enzymatic, 2003, 22: 89.

[10] Zhou M. Q., Hou Y. P., Hamza A., Zhan C. G., Bugni T. S., Thorson J. S. Org. Lett., 2012, 14: 5424.

[11] Jin Y., Chen S. W., Tian X. Biorg. Med. Chem., 2006, 14: 3062.

[12] Gadjeva V. G. Int. J. Pharm., 2002, 247: 39.

[13] Jing X. H., Zhang J. Q., Zhang Z. W., Tian X. Chem. Res. Chinese Universities, 2010, 26(5): 753.

[14] Yang L., Liu Y. Q., Tan H., Li W. G., Tian X. Nat. Prod. Res., 2007, 21: 998.

[15] Liu Y., Wang M. J., Zhang Z. J., Morris-Natschke S. L., Goto M., Jing T., Liu Y. Q., Wang C. Y., Xuan T., Yang X. M. Med. Chem. Res., 2014, 23: 3269.

[16] Liu Y. Q., Ohkoshi E., Li L. H., Yang L., Lee K. H. Biorg. Med. Chem. Lett., 2011, 22: 920.

[17] Liu Y. Q., Dai W., Tian J., Yang L., Feng G., Zhou X. W., Kou L., Zhao Y. L., Li W. Q., Li L. H. Heteroat. Chem., 2011, 22: 687.

[18] Liu Y. Q., Tian X. Synth. Commun., 2005, 35: 2749.

[19] Naik N., Braslau R. Tetrahedron, 1998, 54: 667.

[20] Soule B. P., Hyodo F., Matsumoto K., Simone N. L., Cook J. A., Krishna M. C., Mitchell J. B. Free Radic. Biol. Med., 2007, 42: 1632.

[21] Zakrzewski J., Krawczyk M. Heterocycl. Commun., 2014, 20: 89.

[22] Wu Y., Hirai Y., Tsunobuchi Y., Tokoro H., Eimura H., Yoshio M., Ohkoshi S., Kato T. Chem. Sci., 2012, 3: 3007.

[23] Morrison A., Davies A. P. Biol. Mass Spectrom., 1970, 3: 353.